|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.04/-0.75
|
企業價值
6.12M
|
資產負債 |
每股賬面淨值
0.24
|
現金流量 |
現金流量率
--
|
損益表 |
收益
109.00K
|
每股收益
0.03
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/24 23:59 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |